RFK Jr.’s vaccine panel backs insurance coverage for Covid shots

The advisory committee of the government unanimously voted on Friday to recommend that individuals aged 6 months and older should have a discussion with their healthcare providers regarding the risks and benefits of Covid-19 vaccines before making a decision to get vaccinated. This decision deviates from previous recommendations that urged the majority of Americans to get vaccinated, but it ensures that insurance coverage will be maintained for those who choose to get vaccinated.

A spokesperson from the Health and Human Services Department mentioned that this vote guarantees coverage for immunization through various payment mechanisms, including entitlement programs like Medicaid, Children’s Health Insurance Program, and Medicare, as well as insurance plans from the federal health insurance marketplace.

The committee’s recommendation extends to a broader population compared to the Food and Drug Administration’s limited approval of updated vaccines for individuals above the age of 65 or those with risk factors. This discrepancy between ACIP and FDA decisions, according to Yale health policy researcher Jason Schwartz, could create confusion among millions of people regarding Covid vaccinations.

Despite protecting insurance coverage, the limited approvals by the FDA might pose challenges for healthy individuals in accessing Covid vaccinations without a doctor’s prescription.

Following a thorough debate, the committee declined a proposal to mandate prescriptions for Covid vaccines at the state level. The tie-breaking vote was cast by Chair Martin Kulldorff, resulting in a 6-6 decision. ACIP typically does not intervene in the prescription requirements as it falls under the jurisdiction of the FDA.

Additionally, the committee recommended that the CDC urge healthcare providers to include more information about the risks and uncertainties associated with vaccines in the information statements provided to patients. They also advised healthcare providers to engage in discussions with patients about the risks and benefits of vaccination.

The fate of Covid-19 vaccines had been uncertain due to the undisclosed voting questions considered by ACIP, leading to a disjointed discussion during the meeting. The committee raised doubts about the safety and efficacy of mRNA Covid-19 vaccines, particularly questioning the reliability of data on Covid-related hospitalization rates.

Most concerns expressed were theoretical, including the potential nonspecific effects of vaccine materials on the body. However, some concerns were grounded in data, such as the presentation on myocarditis rates among Covid vaccine recipients.

Pfizer and Moderna conducted initial randomized controlled trials with over 43,000 and 30,000 participants, respectively, demonstrating a 90% efficacy rate in preventing illness. While the effectiveness in preventing illness has decreased with virus variations and increased natural immunity, protection against severe disease remains strong according to CDC data.

The FDA has approved updated Covid-19 vaccines from Pfizer, Moderna, and Novavax for individuals over 65 or with underlying risk factors. This move, diverging from the typical process where the FDA determines safety and efficacy while the CDC advises on vaccine recipients, raised concerns among public health experts regarding vaccine access.

Despite the FDA restrictions, private health insurers have committed to covering updated Covid-19 vaccines this year regardless of regulatory limitations, ensuring continued access. ACIP’s recommendation mandates public health insurers to cover Covid vaccinations as well.

Sanofi, the distributor of Novavax’s Covid vaccine, expressed optimism following the vote, emphasizing continued access and coverage for eligible individuals who wish to receive vaccination for prevention.

The committee also postponed a vote on delaying the first hepatitis B vaccine dose for newborns, a decision opposed by public health experts. They also limited access to the combined measles, mumps, rubella, and varicella vaccine for children under 4, in favor of separate doses for MMR and varicella vaccines.